Verena Ramirez Campos

Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study

Messoud Ashina, Joshua M. Cohen, Maja Galić et al. · The Journal of Headache and Pain · 2021 · 40 citations · Full text

Adverse Events Reported with Therapies Targeting the CGRP Pathway During the First 6 Months Post-launch: A Retrospective Analysis Using the FDA Adverse Events Reporting System

Stephen D. Silberstein, Shoshana Reshef, Joshua M. Cohen et al. · Advances in Therapy · 2022 · 39 citations · Full text

Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies

Stephanie J. Nahas, Steffen Naegel, Joshua M. Cohen et al. · The Journal of Headache and Pain · 2021 · 28 citations · Full text

Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine‐preventive medications in the phase 3b FOCUS study

Egilius L.H. Spierings, Xiaoping Ning, Verena Ramirez Campos et al. · Headache The Journal of Head and Face Pain · 2021 · 26 citations · Full text

Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study

Richard B. Lipton, Joshua M. Cohen, Kristen Bibeau et al. · Headache The Journal of Head and Face Pain · 2020 · 23 citations · Full text